209 related articles for article (PubMed ID: 6339024)
41. Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group.
Thornes D; Daly L; Lynch G; Browne H; Tanner A; Keane F; O'Loughlin S; Corrigan T; Daly P; Edwards G
Eur J Surg Oncol; 1989 Oct; 15(5):431-5. PubMed ID: 2676609
[TBL] [Abstract][Full Text] [Related]
42. Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers.
Bergmann L
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S31-6. PubMed ID: 2697576
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
Spitler LE; Sagebiel R
N Engl J Med; 1980 Nov; 303(20):1143-7. PubMed ID: 6999349
[TBL] [Abstract][Full Text] [Related]
44. Clinical immunotherapy experiences in the Southeastern Cancer Study Group.
Gordon DS
Dev Biol Stand; 1977 Apr 13-15; 38():567-72. PubMed ID: 344110
[TBL] [Abstract][Full Text] [Related]
45. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
46. [Melanoma therapy].
Kleeberg UR
Dtsch Med Wochenschr; 1976 Jun; 101(23):904-8. PubMed ID: 773624
[No Abstract] [Full Text] [Related]
47. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of malignant melanoma (author's transl)].
Civatte J; Jourdain JC
MMW Munch Med Wochenschr; 1978 Mar; 120(12):403-6. PubMed ID: 306028
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
Knost JA; Reynolds V; Greco FA; Oldham RK
J Surg Oncol; 1982 Mar; 19(3):165-70. PubMed ID: 7040820
[No Abstract] [Full Text] [Related]
50. Adjuvant therapy of malignant melanoma.
Vosika GJ
Minn Med; 1979 Jul; 62(7):515-7. PubMed ID: 386072
[No Abstract] [Full Text] [Related]
51. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
52. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Abdi EA; Hanson J; McPherson TA
Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
[TBL] [Abstract][Full Text] [Related]
53. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
[TBL] [Abstract][Full Text] [Related]
54. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Thatcher N; Blackledge G; Palmer MK; Crowther D
Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
[No Abstract] [Full Text] [Related]
55. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
Wätzig V; Knopf B
Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
[TBL] [Abstract][Full Text] [Related]
56. [Adjuvant therapy of malignant melanoma].
Franke W; Neumann NJ; Ruzicka T; Schulte KW
Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
[TBL] [Abstract][Full Text] [Related]
57. Treatment of malignant skin tumours with oral administration of BCG in enteric-coated capsules.
Ishihara K; Ikeda S; Arai E; Sawada T
Dev Biol Stand; 1986; 58 ( Pt A)():465-74. PubMed ID: 3596050
[TBL] [Abstract][Full Text] [Related]
58. [5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
Comella G; Mastro AA; Comella P; Castello G; De Simone G; Cerra R; Zarrilli D
Minerva Med; 1986 Mar; 77(13):507-10. PubMed ID: 3703343
[No Abstract] [Full Text] [Related]
59. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.
Hill GJ; Moss SE; Golomb FM; Grage TB; Fletcher WS; Minton JP; Krementz ET
Cancer; 1981 Jun; 47(11):2556-62. PubMed ID: 7020916
[TBL] [Abstract][Full Text] [Related]
60. Intralesional BCG application in malignant melanoma.
Sopková B; Kolár V
Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
